Catalyst Funds Management Pty LTD Halozyme Therapeutics, Inc. Transaction History
Catalyst Funds Management Pty LTD
- $662 Billion
- Q3 2025
A detailed history of Catalyst Funds Management Pty LTD transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Catalyst Funds Management Pty LTD holds 43,800 shares of HALO stock, worth $3.07 Million. This represents 0.49% of its overall portfolio holdings.
Number of Shares
43,800Holding current value
$3.07 Million% of portfolio
0.49%Shares
3 transactions
Others Institutions Holding HALO
# of Institutions
666Shares Held
128MCall Options Held
626KPut Options Held
455K-
Black Rock Inc. New York, NY17.6MShares$1.23 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.6MShares$814 Million0.01% of portfolio
-
State Street Corp Boston, MA5.02MShares$351 Million0.01% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA3.29MShares$230 Million0.16% of portfolio
-
Invesco Ltd. Atlanta, GA3.25MShares$227 Million0.04% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $9.75B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...